Original Article This work is licensed under the Creative Commons Attribution 4.0 License. Published by Pacifc Group of e-Journals (PaGe) To Study Clinicopathological and Immunohistochemical Expression of Estrogen Receptor, Progesterone Receptor and Her-2/Neu in Prostate Carcinoma Introduction Prostate cancer (PCa) is continually a challenge as one of the leading causes of cancer-related death amongst men. In the developed countries PCa is one of the most common cancers. [1] Approximately 95% of PCa are adenocarcinomas. [2] Gleason grading is the most widely used and accepted histopathological method for providing information regarding PCa prognosis. It is very essential to identify tumor markers which can act as targets for new therapeutic strategies and can act as prognostic indicators in Prostatic Cancer management and disease free or relapse-free survival. The estrogens play an important role in the male sex hormone secretion as well as growth, diferentiation and homeostasis of normal prostate tissue. Estrogen Receptor (ɑ and β) belong to family of ligand-modulated transcription factors (TCFs), also known as nuclear receptors which are often altered in PCa. [3] Progesterone receptor (PR) belongs to steroid receptor superfamily. Stromal PR positivity may show an inhibitory efect on reactive stromal development and BPH but leads to PCa progression. So, it can be used as a potential therapeutic agent and a potential biomarker in PCa management. [4] HER-2/neu is an oncoprotein. It is one of the four transmembrane receptors that belong to the erB family. It forms heterodimers by binding to specifc ligands, enhancing cell signaling and assisting in cell growth and diferentiation. [5] HER-2/neu overexpression in PCa might have a role in invasion of tumor, its aggressiveness and metastatic potentiality. This can also shed light on the role of Transutuzumab in the treatment of Patients with PCa. [6] Materials and Methods This study was conducted on 50 histopathologically proven cases of prostatic carcinoma. Blocks after cutting were stained with Hematoxylin and Eosin stain and were studied for classifcation and histopathological grading. Immunohistochemistry of the tumours was done for ER and PR and HER-2/neu. Positive and negative controls were run with every batch of the IHC. Test sections showed positivity in the form of specifc color. PR Scoring System: The degree of PR expression by IHC was calculated according to both dominant staining intensity and density in both TE and TS. [7] Integrated score = (Staining intensity + Score of percentage of positive cells)/2 Negative result = 0 Low positivity = <1.75 High positivity = >1.75 Manpreet Kaur 1 *, Menka Khanna 1 , Harjot Kaur 1 and Rajeev Gupta 2 1 Department of Pathology, SGRD, Amritsar 2 Department of Medicine, SGRD, Amritsar ABSTRACT Background: Prostate carcinoma is leading cause of cancer related deaths amongst men. This study evaluated expression of ER, PR, HER- 2/neu in Prostatic carcinoma and its correlation with Gleason score and other clinical parameters. Methods: 50 histopathologically proven PCa cases were subjected to IHC for ER, PR, HER-2/neu. Result: Most common age group involved was 61-80years. Retention of urine was most frequent complaint. Most prominent Gleason score was (3+4) and group grade was 2. ER expression in tumor epithelial cells was 24% and in stromal cells was 36%. PR expression in stromal cells was 32%. HER-2/neu Cytoplasmic positivity was seen in 6% cases. It was seen that with increase in Gleason grade, ER, PR, HER-2/neu positivity was decreased. Conclusion: ER, PR, HER-2/neu can be used as biomarkers in PCa management. Keywords: Prostate Carcinoma, ER, PR, HER-2/neu, Biomarkers DOI: 10.21276/APALM.3001